☆ 4.7 Article

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

JAMA NETWORK OPEN (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress

Shun Lu et al.

Summary: The LAURA trial aims to evaluate the efficacy and safety of osimertinib as maintenance therapy in patients with locally advanced, EGFR mutation-positive stage III NSCLC. Patients meeting specific criteria will be randomized into either the osimertinib or placebo group, with the primary objective being to assess osimertinib's progression-free survival (PFS) confirmed by independent review.

CLINICAL LUNG CANCER (2021)

Add to Collection

Article Oncology

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial

Corinne Faivre-Finn et al.

Summary: In the Phase 3, placebo-controlled PACIFIC trial, consolidative durvalumab after chemoradiotherapy showed significant improvements in overall survival and progression-free survival for patients with unresectable, stage III NSCLC, with consistent benefits observed approximately 4 years after treatment. Durvalumab demonstrated durable benefits with a higher 4-year survival rate and progression-free survival rate compared to placebo.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Jacqueline V. Aredo et al.

Summary: Consolidation durvalumab did not benefit patients with EGFR-mutated unresectable stage III NSCLC and was associated with a high frequency of immune related adverse events. Patients who switched to osimertinib after durvalumab treatment may be more susceptible to incident adverse events. Further investigation is needed for concurrent CRT with induction or consolidation EGFR TKIs as definitive treatment.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo Negrao et al.

Summary: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

Marina Chiara Garassino et al.

LUNG CANCER (2020)

Add to Collection

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

A. J. Schoenfeld et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers

Michael Offin et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer

Yasuo Oshima et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Critical Care Medicine

The Eighth Edition Lung Cancer Stage Classification

Frank C. Detterbeck et al.

CHEST (2017)

Add to Collection

Review Oncology

The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification

William D. Travis et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

Add to Collection

Article Multidisciplinary Sciences

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Naiyer A. Rizvi et al.

SCIENCE (2015)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.